Transform Your Future: Ace the 2025 Certified Diabetes Educator Exam!

SGLT2 inhibitors, a class of medications used to manage type 2 diabetes, are recognized by their unique suffix, specifically those that end in -flozin. These medications work by blocking the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which reduces glucose reabsorption and increases glucose excretion in the urine. This mechanism helps to lower blood glucose levels in individuals with diabetes.

The other medication classes provided in the options have distinct endings that reflect different pharmacological properties and therapeutic effects. For example, medications that end in -litazone are typically thiazolidinediones, which work primarily by improving insulin sensitivity. Those ending in -gliptin are DPP-4 inhibitors, which enhance incretin levels to facilitate insulin secretion in response to meals. Medications labeled with the suffix -metformin refer to metformin itself, which primarily decreases hepatic glucose production and improves insulin sensitivity. Each of these classes serves a different role in diabetes management, further highlighting the specific action of SGLT2 inhibitors associated with the suffix -flozin.